DNA regulatory elements in glioblastoma cells

DNA regulatory elements in glioblastoma cells are stretches of non-coding DNA—such as **promoters**, **enhancers**, and **insulators**—that determine the activation or silencing of genes pivotal for tumor growth, progression, and heterogeneity[4][3]. These elements mediate interactions with transcription factors, chromatin remodelers, and epigenetic enzymes, thereby shaping subtype-specific gene expression landscapes and plasticity across tumor cells. Dysregulation of these elements, such as altered DNA methylation patterns (e.g., MGMT promoter methylation or the G-CIMP phenotype), contributes to glioblastoma pathogenesis, influences molecular classification, prognosis, and impacts response to therapies—though the elements themselves are not typically drugged directly[1][3][4]. Tumor-specific regulatory signatures and chromatin states are major determinants of glioblastoma subtype identity, therapeutic vulnerability, and resistance[4][3]. To summarize: "DNA regulatory elements in glioblastoma cells" is too broad and mechanistically oriented to serve as a canonical drug target entry; the actionable therapeutic focus usually shifts to the proteins or enzymes modulating these DNA regions rather than the DNA sequences themselves[3][4][1][5][2].

Other names

DNA cis-regulatory elementsenhancerspromotersDNA regulatory regionschromatin regulatory sites

Indirect — drugs may act by: - Epigenetic modification (e.g., altering methylation/acetylation of regulatory regions) - Inhibiting transcription factors that bind regulatory DNA - Modulating chromatin remodeling at regulatory sites